BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 30617648)

  • 1. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
    Hashimoto T; Kurokawa Y; Takahashi T; Miyazaki Y; Tanaka K; Makino T; Yamasaki M; Nakajima K; Ikeda JI; Mori M; Doki Y
    Gastric Cancer; 2019 Jul; 22(4):785-792. PubMed ID: 30617648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer.
    Haron NH; Mohamad Hanif EA; Abdul Manaf MR; Yaakub JA; Harun R; Mohamed R; Mohamed Rose I
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):509-517. PubMed ID: 30803214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
    Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
    Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
    Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
    Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
    Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
    J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
    Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
    Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
    Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
    J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
    Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F;
    Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
    Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
    Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
    J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
    Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
    Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].
    Wang XY; Hu YJ; Dong K; Zhao C; Huang XZ; Lian SY; Sun Y
    Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1114-1119. PubMed ID: 33152814
    [No Abstract]   [Full Text] [Related]  

  • 16. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
    Noepel-Duennebacke S; Juette H; Schulmann K; Graeven U; Porschen R; Stoehlmacher J; Hegewisch-Becker S; Raulf A; Arnold D; Reinacher-Schick A; Tannapfel A
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3063-3072. PubMed ID: 33675399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
    Rowe M; Krishnan R; Mills A; Ring K
    Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Du Q; Che J; Jiang X; Li L; Luo X; Li Q
    Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
    Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT
    Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer.
    Yang JH; Kim H; Roh SY; Lee MA; Park JM; Lee HH; Park CH; Lee HH; Jung ES; Lee SH; Lee YJ; Choi MH; Kim O; Kim IH
    Gastric Cancer; 2019 Jan; 22(1):147-154. PubMed ID: 29860599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.